Iohexol is a contrast agent for intrathecal administration used in myelography and contrast enhancement for computerized tomography. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
- Mechanism
- Curator reviewed
Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iohexol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iohexol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.
- Primary indication
- Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.Curator reviewed · 2 structured indications
- Formula / weight
- C19H26I3N3O9 · 821.1379 g/mol (avg)
- First approval
- Canada, 2006 · United States, 1985
- Code names
- WIN-39424
- Brand names
Resolves to
NTHXOOBQLCIOLC-UHFFFAOYSA-NSMILESCC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1IWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Iohexol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account